ILCN Multidisciplinary Forum: Understanding Treatment Options and Resistance in EGFR-positive NSCLC IASLC 59:36 3 years ago 393 Скачать Далее
EGFR-Mutant Lung Cancer & Treatment Options | 2023 Living with EGFR-Mutant Lung Cancer Patient Forum Dana-Farber Cancer Institute 14:24 1 year ago 6 452 Скачать Далее
Understanding NSCLC Treatment When You Have an EGFR Mutation You and Lung Cancer 5:03 3 months ago 1 281 Скачать Далее
Future Research and Treatment Options | 2023 Living with EGFR-Mutant Lung Cancer Patient Forum Dana-Farber Cancer Institute 20:38 1 year ago 2 404 Скачать Далее
ILCN Multidisciplinary Forum: The Role of Liquid Biopsy in NSCLC IASLC 57:19 2 years ago 344 Скачать Далее
Treatment of EGFR Mutated NSCLC - 2022 Program: Targeted Therapies Forum - English GRACE - Global Resource for Advancing Cancer Education 4:02 1 year ago 168 Скачать Далее
Understanding EGFR Resistance in Patients With MET-Amplified NSCLC Targeted Oncology 2:02 4 years ago 397 Скачать Далее
New target for treatment resistance after EGFR inhibitors found in lung cancer study Medical Dialogues 2:20 1 year ago 602 Скачать Далее
Treatment Updates: EGFR-Mutant Lung Cancer | 2024 Living with EGFR-Mutant Lung Cancer Patient Forum Dana-Farber Cancer Institute 14:23 1 month ago 869 Скачать Далее
Understanding, preventing, and delaying EGFR resistance in the era of Osimertinib HMP Education 20:18 5 years ago 6 925 Скачать Далее
Q & A with EGFR-Mutant Lung Cancer Experts | 2023 Living with EGFR-Mutant Lung Cancer Patient Forum Dana-Farber Cancer Institute 5:43 1 year ago 200 Скачать Далее
Advancing Care for Patients With EGFR Mutation–Positive NSCLC: Precision Medicine Strategies PeerView Oncology 53:55 3 years ago 648 Скачать Далее
Acquired Resistance to Osimertinib in EGFR+ NSCLC - 2022 Program: Targeted Therapies Forum - English GRACE - Global Resource for Advancing Cancer Education 2:30 1 year ago 626 Скачать Далее
Q & A with EGFR-Mutant Lung Cancer Experts | 2024 Living with EGFR-Mutant Lung Cancer Patient Forum Dana-Farber Cancer Institute 6:02 1 month ago 49 Скачать Далее
Osimertinib as Frontline Therapy for EGFR-Positive NSCLC OncLive 9:49 6 years ago 2 002 Скачать Далее
Combinations and Other Options for Acquired Resistance in EGFR Mutation-Positive NSCLC GRACE - Global Resource for Advancing Cancer Education 4:26 8 years ago 180 Скачать Далее
Investigating EGFR resistance mutations in routine genomic profiling VJOncology 1:33 3 years ago 120 Скачать Далее
2020 TTF EGFR Breakout PIOTROWSKA Part 1 - Current Options Upon Acquired Resistance to Osimertinib GRACE - Global Resource for Advancing Cancer Education 11:23 3 years ago 166 Скачать Далее
